S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
In a recent transaction reported to the SEC, Daniel J. Gerritzen, the General Counsel and Secretary of OrthoPediatrics Corp. (NASDAQ:KIDS), sold 5,310 shares of the company’s common stock. The shares were sold on March 18 at $24.86 each, totaling approximately $132,006. This sale was made to satisfy tax withholding obligations upon the vesting of restricted shares. The medical device company, currently valued at $614 million, maintains strong liquidity with a current ratio of 6.98, according to InvestingPro data.
Following this transaction, Gerritzen holds 110,767 shares of OrthoPediatrics, which includes restricted stock awards totaling 93,291 shares. The transaction reflects Gerritzen’s ongoing management of his equity holdings in the medical device company headquartered in Warsaw, Indiana. While the company posted impressive revenue growth of 37.65% and maintains a healthy gross profit margin of 72.58%, InvestingPro analysis indicates the company is not yet profitable. Discover more insights and 12+ additional ProTips with an InvestingPro subscription.
In other recent news, OrthoPediatrics Corporation reported its fourth-quarter 2024 earnings, revealing a larger-than-expected loss with an EPS of -$0.69, which missed analysts’ forecast of -$0.30. Despite this, the company’s revenue of $52.7 million exceeded expectations, marking a 40% increase from the previous year. The company projects a revenue growth of 15-18% for 2025 and anticipates its first positive free cash flow by the fourth quarter of that year. Stifel analysts have adjusted the price target for OrthoPediatrics to $32.00 from $40.00, while maintaining a Buy rating, following a more optimistic-than-expected earnings call. The company aims to expand its Specialty Bracing franchise and has outlined several product innovations for a broader rollout in 2025. Management highlighted the strongest U.S. Trauma business in its history, supported by recent set deployments. OrthoPediatrics is also optimistic about gaining further market share and broadening its product portfolio in the pediatric orthopedics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.